FDA Yanks 15 Teva Generic Approvals for Dormant Drugs
Published Date: 5/7/2026
Notice
Summary
The FDA is officially pulling the plug on 15 generic drug approvals from Teva Pharmaceuticals and its related companies because these drugs aren’t being sold anymore. This change kicks in on June 8, 2026, and it won’t cost anyone money or cause shortages since the drugs are off the market. If Teva wants, they can ask to sell these drugs again later without any trouble.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
FDA withdraws 15 generic approvals
The FDA is withdrawing approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants, including Teva Pharmaceuticals USA and related companies, effective June 8, 2026. The listed applicants requested withdrawal and waived their opportunity for a hearing. The withdrawal is without prejudice to refiling, so applicants may submit new applications later.
Existing stock can still be dispensed
If any of the listed drug products are in inventory on June 8, 2026, they may continue to be dispensed until inventories are depleted, the products reach their expiration dates, or they otherwise become violative. After those conditions occur, the products may not be introduced into interstate commerce without an approved application.
FDA says no cost or shortage expected
The FDA states the withdrawals apply to drug products that are no longer marketed and that the change takes effect on June 8, 2026. Because these products are off the market, the action is described as not causing costs to consumers or drug shortages.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-09011 — Determination That MICARDIS (Telmisartan), Tablets, 20 Milligrams and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that MICARDIS tablets (20 mg and 80 mg) were not taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved, helping patients access affordable options without delays. If you use or make these meds, no sudden changes or extra costs are coming your way anytime soon!
Next: 2026-09013 — Final Flood Hazard Determinations
FEMA has finalized updates to flood risk maps for certain communities, changing flood zones and water levels that affect flood insurance rules. Homeowners, renters, and local governments in these areas need to check the new maps by June 23, 2026, to stay protected and insured. These changes could impact insurance costs and building rules, so it’s smart to stay informed and prepared!